Plasma levels of phenylacetic acid, m- and p-hydroxyphenylacetic acid, and platelet monoamine oxidase activity in schizophrenic and other patients.
Blood from chronic schizophrenic patients in two hospitals (A and B) and from institutional and noninstitutional controls was analyzed for platelet monoamine oxidase (MAO) activity toward three different substrates (tryptamine, phenylethylamine, and p-tyramine) and for plasma levels of conjugated and unconjugated phenylacetic acid (PAA) and m- and p-hydroxyphenylacetic acids (mHPA and pHPA). Compared to the controls, schizophrenic patients were found to have significantly reduced MAO activity. Although significant differences were found between unconjugated PAA (reduced) in Hospital B, conjugated pHPA (increased) in Hospital A, and conjugated PAA (increased) in Hospitals A and B and noninstitutional controls, the most consistent significant finding was a reduced unconjugated mHPA in both groups of schizophrenic patients compared with both control groups.
D014150:Antipsychotic Agents / Q000627:therapeutic use; D001792:Blood Platelets / Q000201:enzymology*; D002908:Chronic Disease; D006801:Humans; D008607:Intellectual Disability / Q000201:enzymology; D008995:Monoamine Oxidase / Q000097:blood*; D010554:Personality Disorders / Q000201:enzymology; D010648:Phenylacetates / Q000097:blood*; D012559:Schizophrenia / Q000201:enzymology*; D013379:Substrate Specificity
D014150:Antipsychotic Agents; D010648:Phenylacetates; C008070:4-hydroxyphenylacetic acid; D008995:Monoamine Oxidase; C025136:phenylacetic acid; C008069:3-hydroxybenzeneacetic acid